CTRI/2013/02/003422尚未招募3 期
Phase III Study Evaluating Efficacy and Safety of low dose Gemcitabine compared to standard dose Gemcitabine with platinum in advanced non-small cell lung cancer
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 308
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients with stage IIIB or IV; histological/ cytological proven NSCLC.
- •2.Signed informed consent.
- •3.Chemonaive patients non small cell lung cancer
- •4.Stage IV disease and III B patients for palliative chemotherapy
- •5.PS 0 to 2
排除标准
- •1.Patients with SVCO, symptomatic brain metastasis
- •2.Patients with uncontrolled cardiac or neurological illness
- •3.Patients with deranged end organ functions â?? ANC <1500/cumm, Platelets <100000/cumm. Creat >1.5xULN, Liver enzymes >5 x ULN, Bilirubin >1.5xULN
- •4.Patients with any other malignancy treated in the last 5 years
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, ßS/ßC GenotypeSickle cell anaemiaMedDRA version: 21.0Level: PTClassification code: 10040641Term: Sickle cell anaemia Class: 100000004850CTIS2023-503247-34-00Vertex Pharmaceuticals Inc.14
进行中（未招募）
3 期
A study to assess the safety and efficacy of a gel treatment in subjects with acne vulgarisAcne vulgarisSkin and Connective Tissue DiseasesISRCTN18067422PPM Services S.A400
进行中（未招募）
3 期
A Phase III Study of ARS-1 Administration in Patients with Food AllegyJPRN-jRCT2031230143Kenya Morita15
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive EsophagitisEUCTR2006-000419-90-LVTAP Pharmaceutical Products Inc.450
进行中（未招募）
不适用
A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive EsophagitisErosive esophagitisEUCTR2006-000419-90-HUTAP Pharmaceutical Products Inc.450